Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gynecologic 1

Conditions

Breast Neoplasms 102Carcinoma, Non-Small-Cell Lung 93Multiple Myeloma 80Prostatic Neoplasms 74Colorectal Neoplasms 59Neoplasms 57Leukemia, Myeloid, Acute 56Lymphoma 48Squamous Cell Carcinoma of Head and Neck 43Lung Neoplasms 39Ovarian Neoplasms 38Melanoma 38Neoplasm Metastasis 36Pancreatic Neoplasms 35Lymphoma, Non-Hodgkin 35Carcinoma, Hepatocellular 34Lymphoma, Large B-Cell, Diffuse 33Sarcoma 31Head and Neck Neoplasms 31Urinary Bladder Neoplasms 30Precursor Cell Lymphoblastic Leukemia-Lymphoma 29Carcinoma, Renal Cell 29Leukemia, Lymphocytic, Chronic, B-Cell 28Hodgkin Disease 28Endometrial Neoplasms 28Triple Negative Breast Neoplasms 27Myelodysplastic Syndromes 26Recurrence 25Hematologic Neoplasms 25Glioma 25

Interventions

temsirolimus 1ixabepilone 1Taxes 1Sirolimus 1Paclitaxel 1Immunoglobulin G 1Epothilones 1Disulfides 1Carboplatin 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Endometrial Adenocarcinoma × 30 days × Clear all
NCT00977574 2026-05-29

Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer

National Cancer Institute (NCI)

Phase 2 Active not recruiting
349 enrolled 11 charts
GynecologicSarcoma

Endometrial Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡